The heterotrimeric AMP-activated protein kinase (AMPK) has a key role in regulating cellular energy metabolism; in response to a fall in intracellular ATP levels it activates energy-producing pathways and inhibits energy-consuming processes 1 . AMPK has been implicated in a number of diseases related to energy metabolism including type 2 diabetes, obesity and, most recently, cancer 2-6 . AMPK is converted from an inactive form to a catalytically competent form by phosphorylation of the activation loop within the kinase domain 7 : AMP binding to the c-regulatory domain promotes phosphorylation by the upstream kinase 8 , protects the enzyme against dephosphorylation, as well as causing allosteric activation 9 . Here we show that ADP binding to just one of the two exchangeable AXP (AMP/ADP/ATP) binding sites on the regulatory domain protects the enzyme from dephosphorylation, although it does not lead to allosteric activation. Our studies show that active mammalian AMPK displays significantly tighter binding to ADP than to Mg-ATP, explaining how the enzyme is regulated under physiological conditions where the concentration of Mg-ATP is higher than that of ADP and much higher than that of AMP. We have determined the crystal structure of an active AMPK complex. The structure shows how the activation loop of the kinase domain is stabilized by the regulatory domain and how the kinase linker region interacts with the regulatory nucleotide-binding site that mediates protection against dephosphorylation. From our biochemical and structural data we develop a model for how the energy status of a cell regulates AMPK activity.
The heterotrimeric AMP-activated protein kinase (AMPK) has a key role in regulating cellular energy metabolism; in response to a fall in intracellular ATP levels it activates energy-producing pathways and inhibits energy-consuming processes 1 . AMPK has been implicated in a number of diseases related to energy metabolism including type 2 diabetes, obesity and, most recently, cancer [2] [3] [4] [5] [6] . AMPK is converted from an inactive form to a catalytically competent form by phosphorylation of the activation loop within the kinase domain 7 : AMP binding to the c-regulatory domain promotes phosphorylation by the upstream kinase 8 , protects the enzyme against dephosphorylation, as well as causing allosteric activation 9 .
Here we show that ADP binding to just one of the two exchangeable AXP (AMP/ADP/ATP) binding sites on the regulatory domain protects the enzyme from dephosphorylation, although it does not lead to allosteric activation. Our studies show that active mammalian AMPK displays significantly tighter binding to ADP than to Mg-ATP, explaining how the enzyme is regulated under physiological conditions where the concentration of Mg-ATP is higher than that of ADP and much higher than that of AMP. We have determined the crystal structure of an active AMPK complex. The structure shows how the activation loop of the kinase domain is stabilized by the regulatory domain and how the kinase linker region interacts with the regulatory nucleotide-binding site that mediates protection against dephosphorylation. From our biochemical and structural data we develop a model for how the energy status of a cell regulates AMPK activity.
At the whole-body level, AMPK is regulated by a diverse range of hormones-for example, leptin 10 , adiponectin 11 , ciliary neurotrophic factor 12 and ghrelin 13 -and it has a role in appetite 13, 14 , glucose, lipid and protein metabolism 1, 3, 15 , cell growth, and cell polarity 2, 4 . AMPK is a heterotrimeric complex comprising an a-catalytic subunit and two regulatory subunits (b and c) 1 . Activation of AMPK requires phosphorylation of Thr 172, which lies in the activation segment of the amino-terminal kinase domain of the a-subunit 7 . Phosphorylation of Thr 172 leads to a several-hundred-fold increase in activity 9, 16 . In mammals, calcium/calmodulin-dependent protein kinase kinase-b (CaMKKb) and LKB1 are the predominant kinases upstream of AMPK, although there is some evidence implicating other upstream kinases 17, 18 . Previous studies have shown that AMP protects against the dephosphorylation of Thr 172 (refs 16, 19) and we recently provided evidence that protection against dephosphorylation is the major physiological mechanism for activation of AMPK 9 . In addition to activation by phosphorylation, AMP causes a 2-5-fold allosteric activation of AMPK depending on the nature of the isoforms present in the AMPK complex 20 . To address this issue we previously investigated the nucleotide-binding properties of the c1 subunit of AMPK and determined the structure of the regulatory core of mammalian AMPK (C-terminal domain of a-subunit, C-terminal domain of b-subunit, full-length c-subunit; hereafter referred to as the regulatory fragment) in complex with nucleotides 21 . Notably, our studies revealed that three of the four potential nucleotide-binding sites are occupied 21 . One of these sites contains a permanently bound AMP molecule (site 4, following nomenclature proposed by ref. 22) , whereas AMP and Mg-ATP compete for binding at the other two sites 21 (site 1 and site 3).
Unlike AMP, ADP has no significant allosteric effect on AMPK isolated from rat liver 23 . Consistent with this, we also found that ADP does not activate recombinant AMPK under conditions where AMP produces a twofold activation ( Fig. 1a ). However, our studies show that ADP provides protection of AMPK from dephosphorylation across a similar range of concentrations as AMP ( Fig. 1b ). We have also shown the same effect using AMPK purified from rat liver ( Supplementary Fig. 2a ). Although Mg-ATP does not protect against dephosphorylation ( Fig. 1c ), it does compete with the protective effect of both AMP and ADP on dephosphorylation ( Fig. 1d ). We have also shown that the protective effect of ADP is lost in a Wolff-Parkinson-White syndrome mutation ( Supplementary Fig. 2b ). We propose that AMP or ADP (AMP/ADP) binding shifts the equilibrium between dephosphorylation-sensitive and -insensitive states, and thus slows, but does not abolish, dephosphorylation of the enzyme by phosphatases.
Extending our earlier work looking at nucleotide binding to the regulatory fragment, we characterized binding of nucleotides to active fulllength AMPK. For these studies we used CaMKKb to stoichiometrically phosphorylate Thr 172 on the activation loop of recombinant fulllength AMPK, we used the coumarin adducts of ATP and ADP as fluorescent reporters of nucleotide binding, and derived the binding parameters for the unlabelled nucleotides by competition experiments ( Fig. 2a ). We verified that the two species bind at the same sites by determining the crystal structures of the regulatory fragment in complex with coumarin-ADP and with ADP ( Supplementary Fig. 3 ). The results show (Table 1 ) that the two exchangeable sites have markedly different affinities for nucleotides. Binding at the tighter of the two sites is at least 30-fold stronger than at the weaker site. Given that under physiological conditions most of the ATP is coordinated to Mg 21 , and that the majority of AMP and ADP is not, we also measured nucleotide binding in the presence of this cation. The data show that Mg-ATP binds up to tenfold weaker than ATP. Thus, active AMPK binds AMP/ADP significantly more strongly than it does Mg-ATP at both exchangeable sites. There are two lines of evidence that lead us to conclude that it is AMP/ADP binding at the weaker of the two exchangeable sites that accounts for the protection of the enzyme against dephosphorylation. The first is that the dose-response curve for AMP/ADP-mediated protection against phosphorylation correlates with the binding curves for these nucleotides at the weaker, rather than the stronger, of the two binding sites (Fig. 1b) . The second comes from our discovery that NADH binds to AMPK. NADH undergoes a significant change in fluorescence upon binding to AMPK. We used this property to establish that the cofactor binds to a single site on the enzyme, with a dissociation constant (K d ) of about 50 mM (Fig. 2b, inset) . NADH binding is competed by AXPs binding to the stronger, but not the weaker, of the two exchangeable sites ( Fig. 2b and Table 1 ). When we repeated the ADP protection against dephosphorylation experiments using a range of NADH concentrations, we found no evidence for NADH competing with the protective effect of ADP on dephosphorylation, whereas NADH and ADP both compete with AMP for allosteric activation of the enzyme ( Supplementary Fig. 4 ). This observation indicates that it is AMP/ADP binding at the weaker of the two exchangeable sites, the one that does not bind NADH, that is responsible for protection against dephosphorylation. We also carried out co-crystallization of the regulatory fragment with one molar equivalent of ADP ( Supplementary Fig. 5 ). The resulting electron density map showed full occupancy of ADP at site 1 and no detectable density at site 3, identifying site 3 as the weaker binding site. We can therefore assign the allosteric effect to AMP binding at the tighter site 1, and protection against dephosphorylation is mediated by AMP/ADP binding at the weaker site 3.
Previous studies on the regulation of AMPK have focused on the role of AMP because it allosterically activates the enzyme 15 whereas ADP does not. However, phosphorylation remains central to AMPK regulation as the enzyme is inactive in the absence of Thr 172 phosphorylation 7, 16 . Under optimal conditions, mammalian cells maintain ATP at a high level relative to ADP and AMP. Typical concentrations of free adenine nucleotides in mammalian cells lie in the range of 3,000-8,000 mM for ATP, 50-200 mM for ADP and 0.5-5 mM for AMP [24] [25] [26] . Because the free concentration of ADP is between 10-to 400-fold higher than AMP, and their binding constants are similar, ADP will be more successful at competing with Mg-ATP than AMP. Therefore, the fact that ADP protects AMPK from dephosphorylation is likely to represent an important physiological mechanism for regulating the activity of the enzyme.
We have also determined the crystal structure of an active form of the enzyme that encompasses the whole of the catalytic a-subunit. The construct used is shown in Fig. 3a (details of its design are given in Supplementary Fig. 6 ). From the best samples we collected a data set to 3.3 Å Bragg spacing, after screening about 100 crystals, and solved the structure by molecular replacement using independent models for the regulatory fragment (Protein Data Bank 2V8Q) 21 and the kinase domain (Protein Data Bank 2H6D) 27 . Although the data set is at medium resolution, the molecular replacement solution was robust and yielded initial electron density that revealed the location of many components that were not present in the original model. As might be expected for a structure of this complexity and resolution, some parts of the molecule are better defined than others. For example, the activation loop of the kinase domain, which is packed against the regulatory fragment, has better defined electron density than loops on the surface of the complex, which often show continuous main-chain density but lack side-chain features. Overall, the most important features of the current structure concern the architecture of the complex, particularly the relationships between the a-kinase domain and the a-linker with the regulatory fragment (omit maps for these regions are presented in Supplementary Fig. 7) .
The structure is shown in Ribbons representation (Fig. 3b, c and Supplementary Fig. 8 ) and in space-filling representation before and after the kinase domain and the linker region have been rotated away from the complex to display their contact regions (Fig. 3d ). The first of these interfaces involves the kinase domain and has a surface area of about 1,100 Å 2 . This relatively modest contact area is consistent with the observation that specific protease cleavage of the linker between the kinase domain and the C-terminal domain of the a-subunit leads to material that separates into two components (kinase domain plus regulatory fragment) after gel filtration. A significant part of the 
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contact area involves the activation loop of the kinase interacting predominantly with the C terminus of the b-domain (Fig. 3c ). Unlike previous structures of the isolated and non-phosphorylated kinase domain, the phosphorylated activation loop in our structure is well ordered, as evidenced by electron density maps ( Supplementary Fig.  7) . The small lobe of the kinase is in a more closed conformation relative to the unphosphorylated (and thus inactive) isolated kinase domain structure 27 ( Supplementary Fig. 9 ). The fact that the activation loop mediates the interaction of the kinase domain with the regulatory fragment means that, in this conformation, Thr 172 is protected from access by phosphatases. This idea is strongly supported by site-directed mutagenesis experiments: mutation of b1 His 233 (corresponding to His-235 in b2) at the interface with the kinase domain ( Fig. 3c ) results in an enzyme that is activatable by phosphorylation but that has a significantly increased rate of dephosphorylation in phosphatase assays (Fig. 4a, b ). Another component of the a-subunit-regulatory fragment interaction is provided by a part of the segment of the a-chain that links the N-terminal kinase domain to the C-terminal regulatory fragment, involving residues between a373 and a382 that are largely conserved between a1 and a2 in vertebrates ( Supplementary Fig. 10 ) and which we have called the a-hook structure (Fig. 3b, d) . The a-hook interacts with the c-subunit at the exchangeable binding site 3, with AMP bound, which we have assigned as the weaker of the two sites responsible for mediating AMP/ADP protection against dephosphorylation. The hook makes a lid over the nucleotide-binding site that accounts for a buried surface area of about 500 Å 2 . We obtained crystals of this construct with AMP added to the crystallization mixture, and an AMP molecule is clearly identifiable in the electron density maps at site 3, as well as at the non-exchangeable site. Although we did not see AMP at site 1 in the initial crystals, we subsequently achieved good occupancy at this site by maintaining a higher concentration of AMP during crystallization and handling procedures (data not shown). In contrast, we think that the AMP at site 3 is held in place by the arrangement of the a-hook and that it would have to dissociate before the bound AMP could be released and then exchanged. On the basis of superposition of our earlier structures of the regulatory fragment of AMPK in complex with ADP and Mg-ATP and the structure presented here, we think that the a-hook sequence cannot interact with site 3 when Mg-ATP is bound, mainly Asp α166
Arg α464
Leu α189
Glu α168
Phe α169
Pro β209 Pro β206
His β240 
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due to the change in conformation of Arg 69 of the c-subunit, which would generate a steric clash with the a-hook ( Supplementary Fig. 11 ).
To test the role of the a-hook in mediating protection against dephosphorylation we generated a mutant in this region (R375Q/T377A/ D379A/E380A). The resulting enzyme was allosterically activated by AMP but was not subject to protection against dephosphorylation by AMP or ADP (Fig. 4c, d) . Interestingly, the mutation at His 233 described above does retain some protective effect of AMP/ADP (Fig. 4a, b) . Given that this mutation would be expected to weaken the interaction between the kinase domain and the regulatory fragment, but not block it, it seems reasonable that AMP/ADP binding would still help to order the a-hook and thus facilitate the recruitment of the kinase domain. Taking our biochemical and structural data together, we propose the following model for how AMP/ADP, but not Mg-ATP, protects AMPK against dephosphorylation, and thus inactivation ( Supplementary Fig.  1 ). We have demonstrated that the protective effect of AMP/ADP is mediated by its binding to the weaker of the two exchangeable sites, which we have identified as site 3. We have also shown that the a-hook region binds into this site in the presence of AMP and predict that the same situation would occur with ADP. We further suggest that binding of the a-hook acts to restrict the flexibility of the preceding a-linker region (residues 300-370) and, in so doing, promotes the interaction of the kinase domain with the regulatory fragment seen in our crystal structure. This interaction, which mostly involves contacts between the activation loop and the C-terminal domain of b, would therefore act to protect Thr 172 against dephosphorylation. Because the interaction surface of the a-hook with the regulatory fragment is relatively small it is likely that there is a dynamic equilibrium between the a-hook-bound and a-hook-unbound species. If, as our structure indicates, AMP/ADP binding favours the a-hook-bound species but Mg-ATP binding drives formation of the a-hook-unbound species, then the competitive binding of AMP/ADP versus Mg-ATP would control the extent to which the enzyme was protected from dephosphorylation and inactivation.
METHODS SUMMARY
AMPK complexes were expressed in Escherichia coli BL21 (DE3) cells, purified by affinity chromatography using nickel-Sepharose and phosphorylated by incubation with CaMKKb as described previously 9 . AMPK activity was determined using 0.2 mM SAMS peptide 9 , 0.2 mM ATP and 5 mM MgCl 2 . Dephosphorylation of AMPK by recombinant PP2C-a was monitored either by measuring AMPK activity using the SAMS peptide assay or by western blotting of phospho-T172. Western blot signals for phospho-T172 and total AMPK a-subunit (determined using sheep anti-a1oranti-a2 antibodies) were quantified using the Li-Cor Odyssey infrared imaging system. Uncorrected fluorescence spectra of the nucleotides (39-(7-diethylaminocoumarin-3-carbonylamino)-39-deoxy-ADP (C-ADP), and 39-(7-diethylaminocoumarin-3-carbonylamino)-39-deoxy-ATP (C-ATP) (both gifts from M. Webb)) and NADH and their complexes wererecorded at20 uC using aJasco FP-6300fluorimeter. Binding of nucleotides was monitored by titrating nucleotide (4-10 mM) with AMPK. Dissociation constants for AMP, ADP and ATP were determined using competition assays. The engineered crystallization construct was expressed as a His-tag fusion protein in E. coli. Purified protein was phosphorylated using CAMKKb before mixing with AMP and staurosporine. Crystals were grown by the hanging-drop method using isopropanol and MPD as precipitant. Diffraction data were collected on the Diamond Light Source, Oxford and processed using Denzo and Scalepack 28 . The structure was solved by molecular replacement using Amore 29 and standard refinement was carried out with Refmac5 30 with manual model building with COOT. Figures were created with Pymol (http://pymol.sourceforge.net/).
